Tamsulosin and Solifenacin

BPH & Drugs for Urinary Retention · Antimuscarinic/Selective alpha-1 blocker

Indications

Moderate to severe urinary frequency, urgency, and obstructive symptoms associated with benign prostatic hyperplasia in males when monotherapy is ineffective.

Dosage

Adults: 1 tab once daily. Children: Not recommended.

Adverse Effects

Dry mouth, constipation, dyspepsia, abdominal pain, dizziness, blurred vision, fatigue, ejaculation disorder (including retrograde ejaculation). Acute urinary retention (uncommon).

Risk Factor (Pregnancy/Lactation)

Contraindications: Severe hepatic impairment (Child-Pugh score >9). Haemodialysis patients. Severe GI conditions (including toxic megacolon). Myasthenia gravis, narrow-angle glaucoma. Patients with a history of orthostatic hypotension. Females. Precautions: Severe renal impairment (CrCl =30 mL/min). Moderate hepatic impairment (Child-Pugh score 7-9). Hiatus hernia. Gastroesophageal reflux.

Interactions

Ketoconazole, ritonavir, nelfinavir, itraconazole, verapamil, rifampicin.

Advice to Patient

Take with or without meals. Swallow whole. Do not chew, crush or break tablet.

Pharmacokinetics

TAMSULOSIN: Note: Pharmacokinetics in paediatric patients (ages 2-16 yrs) were found to be similar to adult values. Absorption: >90%. Metabolism: Hepatic (extensive). Bioavailability: Fasting: 30% increase. Steady-state: By the 5th day of once-daily dosing. Half-life elimination: Healthy volunteers: 9-13 hrs. Target population: 14-15 hrs. Time to peak: Fasting: 4-5 hrs. With food: 6-7 hrs. Excretion: Urine (76%). Faeces (21%). SOLIFENACIN: Metabolism: Extensively hepatic. Bioavailability: Approx. 90%. Half-life elimination: 45-68 hrs following chronic dosing; prolonged in severe renal (CrCl <30 mL/min) or moderate hepatic (Child-Pugh class B) impairment. Time to peak, plasma: 3-8 hrs. Excretion: Urine (69.2%). Faeces (22.5%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.